Viking Therapeutics Inc. (NASDAQ: VKTX) presented data from its 13-week Phase 2 trial of oral VK2735 at the European Congress ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE